

Products People Passion

JULY 2025

Legal Disclaimer

All trademarks used or mentioned here are protected by law. Tillotts Pharma AG's trademarks include Tillotts®, Asacol™, OPTICORE™, Octasa™, Fivasa™, Yaldigo™, Kiudro™, Lixacol™, Asacolon™, Yaldigo™, Colpermin™, VistaPrep™, Entocort™, Entocir™, Entocord™, Budecol™ and Zentacort™ and are either registered or applied for in up to 70 countries (transfer of registrations to Tillotts pending in certain countries). The rights to Asacol, including the rights to the trademark, are owned by Tillotts in various countries except for the following: Switzerland, USA, United Kingdom, Canada, Italy, Belgium, the Netherlands and Luxembourg. The rights to Colpermin, including the rights to the trademark, are owned by Tillotts in various countries except for the following: United Kingdom and Ireland. The rights to Entocort, including the rights to the trademark, are owned by Tillotts in various countries (transfer of market authorisations pending) except for the USA.

This presentation may contain forward-looking statements that involve known and unknown risks, uncertainties, and various factors that may cause actual results to differ materially from those reflected in the forward-looking statements. Should one or more of these factors materialise, or should the assumptions underlying the presentation prove inaccurate, actual results may differ materially from those described in the presentation.

This presentation incorporates certain data supplied by third parties. Tillotts Pharma cannot guarantee the accuracy, completeness or integrity of third party data.

Product information in this presentation is a summary for general information purposes regarding the activities of Tillotts Pharma. More information may be available from local regulatory authorities, but not all products are available in each country. Please consult a healthcare professional for further information.

© Copyright Tillotts Pharma AG. All rights reserved. This presentation and all information contained herein are protected by copyright law and no part may be reproduced, published, distributed, displayed, performed, copied or stored, or any derivative work created, for any reason without the express, written permission of Tillotts Pharma AG.

Company Overview

Company Overview

FOUNDED

1963 Tillotts Laboratories Ltd,
Great Britain

TOTAL INCOME (2024)

CHF 294M

Compound Annual Growth Rate 2010-2024: 10.1%

EMPLOYEES

408
As of July 2025



LOCATION



Rheinfelden AG,
Switzerland
(Headquarters)

Ziefen BL,
Switzerland
(Contract Manufacturing)



AFFILIATES covering 23 countries

2004* Ireland

2008* Sweden (Nordics & Baltics)

2010 UK & Czech Republic

2011§ Spain & Portugal

2013° Germany

2016** France & Benelux

2021 Italy, Greece,
Switzerland,
Austria

OUR PRODUCTS

ASACOL™
mesalazine

Entocort®
budesonide

DIFICLIR™
fidaxomicin

Colpermin™
187 mg PEPERCIMIN OIL

VistaPrep™
Powder for oral solution

BUSINESS MODEL

Sales in

Around 52 countries

through a network of own affiliates and
selected licensees and distributors

* Year of registration, promotional activities started in the following year

° Promotional activities started in 2017

§ Portugal was added to the Spanish affiliate in 2020

** Benelux was added to the French affiliate in 2021

Parent Company Overview

Zeria Pharmaceutical Co., Ltd.

ZERIA SHINYAKU KOGYO K.K.



ESTABLISHED

1955

REPRESENTATIVE

Mitsuhiro Ibe
President & COO

EMPLOYEES

1,777 Employees

As of 31st of March 2024




BUSINESS OPERATIONS


Manufacture, sales, import and export of

- Pharmaceuticals,
- Non-pharmaceuticals
- Veterinary pharmaceuticals
- Agricultural chemicals
- Industrial chemicals and reagents
- Cosmetics
- Health foods
- Alcoholic beverages
- Soft drinks
- Food additives
- Livestock feed
- Hygienic goods
- Medical devices
- Health equipment
- Hygiene facilities and equipment
- Beauty appliances
- Measuring equipment
- Analytical equipment


History



History



History



Tillotts named one of best employers in Switzerland by GPTW®

Tillotts integrates Portugal as part of the Spanish affiliate

Tillotts acquires DIFICLIR™ from Astellas Pharma

DIFICLIR
fidaxomicin

Tillotts Pharma AG announces the launch of Octasa® 800mg Tablets in Canada

Office renovations start at the Tillotts head-quarters in Rheinfelden



History



Tillotts celebrates 15 years as a part of the Zeria Group

Tillotts reaches a number of more than 400 employees worldwide

Mage Biologics announces first subject dosed in a Phase 1 trial with MB-001, an orally administered antibody for Inflammatory Bowel Disease

Tillotts Pharma partners with Pioneer for the marketing and distribution of Tillotts' product Asacol® in the People's Republic of China



2024

>>

>>

Our Mission



TILLOTTS PHARMA

Our Mission

We support and collaborate with healthcare professionals around the world to continuously evolve the understanding **in the field of Gastroenterology and other specialist therapeutic areas**.

We deliver high quality medicines and educational support that improve **patient lives**.

We take pride in our **unique culture**, that is based on our **"Corporate Values"**, guiding us in our every day business and allowing our diverse workforce to develop and deliver their full potential. We treat our employees as well as our business partners with **fairness and respect**. In striving towards our **"Vision 2030"**, we always demonstrate **passion, rewarding entrepreneurial spirit and outstanding performance**. We encourage our employees to **see the bigger picture, challenge the status quo and embrace change**.

As an attractive employer, we invest in our people by offering **a state-of-the-art work environment**, and providing room for our employees to create a modern and flexible work-life-balance.

To our shareholders we provide both **value** and **attractive, sustainable returns**.



Our Leadership Team

Tillotts Board of Directors



MR SACHIAKI IBE
Chairman



THOMAS A. TÓTH VON KISKÉR
Chief Executive Officer, Vice Chairman



MR MITSUHIRO IBE
Director, Non-Executive



MR MASAKAZU-SAKURAI
Director, Non-Executive



MR MATTIAS NORRMAN
Director, Non-Executive

Our Leadership Team



Thomas A. Tóth von Kiskér

CEO, Vice Chairman

Thomas A. Tóth von Kiskér has been with Tillotts for more than 20 years starting in Sales & Marketing.

In 2001 he was promoted to Director of Business Development & Licensing and in 2005 to Director of Corporate Development.

In January 2008 he was appointed CEO of Tillotts.

Our Leadership Team

Executive Committee



Thomas A. Tóth von Kiskér, Chief Executive Officer

Thomas A. Tóth von Kiskér has been with Tillotts for more than 20 years starting in Sales & Marketing. In 2001, he was promoted to Director of Business Development & Licensing and in 2005 to Director of Corporate Development. Since January 2008, he has been the CEO of Tillotts.



Johannes Spleiss, Chief Scientific Officer

Johannes Spleiss joined Tillotts in November 1998. He took on positions of increasing responsibility and is now leading R&D, Medical Affairs, Drug Safety and Regulatory Affairs. A chemist by training, he has 30 years of experience in the pharmaceutical industry.



Adrian Hill, Chief Commercial Officer

Adrian Hill joined Tillotts in January 2019. He has more than 30 years of experience in commercial activities including experience in global marketing from several companies including Sanofi, GSK and most recently Kyowa Kirin.



Mirjam von Zedtwitz, Secretary of the Board

Mirjam von Zedtwitz joined Tillotts in July 2024. She is a German qualified attorney with more than 20 years of experience working as in-house counsel in the pharmaceutical, biotechnology and medical technology industry.

Our Leadership Team

Senior Management Committee



Harald Haubitz, Head of Technical Operations

Harald Haubitz joined Tillotts in January 2018. He is a pharmacist by training with over 25 years of experience in the pharmaceutical industry. Previously he held different management positions at Roche and acted as the COO of Acino for several years before he ran his own consultancy business.



Oliver Isch, Head of Finance

Oliver Isch joined Tillotts in 2016 as Senior Business Controller. In September 2024, he was promoted to Head of Finance. Prior to working for Tillotts, he worked in various industries as Controller and Risk Manager. He is a Chartered Expert in Financial and Managerial Accounting and Reporting and has 20 years of experience in this field.



Sandra Annani, Head of Business Initiatives

Sandra Annani joined Tillotts in July 1997 and has since held a variety of commercially focused roles, including actively contributing to the establishment of affiliates across Europe. With a background in Business Administration, she brings valuable expertise and long-standing experience to the company.



Gabriella Schraner, Head of HR

Gabriella Schraner joined Tillotts in 2013. In February 2016, she transitioned into the role Head of HR. She is a Human Resources expert by training with specialization in International HR with more than 10 years of experience. Prior to Tillotts, she mainly worked in the biotechnology industry.



Jan Deresiewicz, Managing Director DACH & Nordics

Jan Deresiewicz joined Tillotts in January 2012. With more than 25 years of pharma experience, he has held Nordic, German and global sales and marketing positions in companies such as Bayer and AstraZeneca.



Christian Weidenfeller, Head of Scientific Affairs Head of Medical Affairs Anti-Infectives

Christian Weidenfeller joined Tillotts in April 2021. He holds a Ph.D. in Biochemistry and has 18 years of experience in the pharmaceutical industry, spanning research, preclinical and clinical development, and Medical Affairs. He has worked with companies such as Merck Serono, EMD Serono, Pfizer, Celgene, and Sunovion across various therapeutic areas.



Mirjam von Zedtwitz, General Counsel

Mirjam von Zedtwitz joined Tillotts in July 2024. She is a German qualified attorney with more than 20 years of experience working as in-house counsel in the pharmaceutical, biotechnology and medical technology industry.

Our Locations

SWITZERLAND HEADQUARTERS


- **Rheinfelden AG** (B15 and Salmenpark)
– Tillotts Pharma AG

CONTRACT MANUFACTURING

- **Ziefen BL**

AFFILIATES IN EUROPE

- **Nordics & Baltics** - Tillotts Pharma AB
- **Ireland** - Tillotts Pharma Limited
- **UK** - Tillotts Pharma UK Limited
- **Czech (incl. Slovakia)** - Tillotts Pharma Czech s.r.o.
- **Spain & Portugal** - Tillotts Pharma Spain S.L.U.
- **Germany** - Tillotts Pharma GmbH
- **France & Benelux** - Tillotts Pharma France SAS
- **Italy (incl. Greece)** - Tillotts Pharma Italy Srl
- **Switzerland (incl. Austria)** - Tillotts Pharma AG



Our Products



TILLOTTS PHARMA

Tillotts Products

ASACOL™

Entocort™
budesonide

DIFICLIR™
fidaxomicin


Colpermin™
187 mg PEPPERMINT OIL

VistaPrep™
Powder for oral solution

GI-health is our passion™